Dr Reddy’s and Natco would together develop these products for registration and global commercialization including regulated markets of the US and EU. Natco shall exclusively manufacture and supply the products for global commercialization by Dr Reddy’s.
As per the agreement, Dr Reddy’s would pay an undisclosed amount as upfront to Natco for securing rights to the product portfolio and capacity required to manufacture the products. In addition both parties have a profit sharing mechanism in their respective designated territories.
Dr Reddy’s would have exclusive commercialization rights for certain products worldwide and territory specific commercialization rights for all other products including the US and EU. Both parties would look to supplement the agreement with future products to expand the strategic collaboration.
Rajeev Nannapaneni, COO of Natco Pharma, said: “We are impressed with Dr Reddy’s commercial infrastructure and commitment to oncology and are happy to come together to deliver value in the oncology space. We look forward to mutually beneficial strategic collaboration.”